Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
ATLANTA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX). The lawsuit alleges
Kyverna Therapeutics Sued for Securities Fraud; Investors Should Contact Block & Leviton to Learn How They Might Recover Losses
10:00am, Tuesday, 10'th Dec 2024
BOSTON, MA / ACCESSWIRE / December 10, 2024 / Block & Leviton announces that a securities fraud lawsuit has been filed against Kyverna Therapeutics, Inc. (Nasdaq:KYTX) and certain of its executives. I
Block & Leviton announces that a securities fraud lawsuit has been filed against Kyverna Therapeutics (Nasdaq: KYTX). Investors should contact the firm.
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
06:35pm, Monday, 09'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities Class Action lawsuit in the Un
Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose KYV-101 Treatment Continues to Demonstrate Robus
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
04:14pm, Wednesday, 13'th Nov 2024
Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Progra
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
08:00am, Monday, 21'st Oct 2024
Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeuti
Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101's initial efficacy and safety profile and broad po
Kyverna Therapeutics Announces Leadership Update
08:00am, Monday, 16'th Sep 2024
– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launc
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An Inquiry
11:00am, Wednesday, 11'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Ther
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Ther
Shareholders With Losses In Kyverna Therapeutics, Inc. Should Contact The Schall Law Firm About A Securities Fraud Investigation
11:00am, Monday, 09'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera
Kyverna Therapeutics Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Join An Inquiry
11:00am, Saturday, 07'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera
Shareholders In Kyverna Therapeutics, Inc. Are Urged To Partake In The Schall Law Firm's Securities Related Investigation
11:00am, Friday, 06'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Investors Should Join The Inquiry
11:00am, Thursday, 05'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera
